Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Relmada Therapeutics Second Quarter 2025 Earnings Conference Call.
Relmada Therapeutics Inc. (RLMD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Driehaus Capital Richard Driehaus | 740,006 | $444,226 | 0% | |
| 2. | Marshall Wace LLP Paul Marshall And Ian Wace | 154,568 | $92,741 | 0% | |
| 3. | Renaissance Technologies Jim Simons | 150,100 | $90,105 | +21% | 0% |
| 4. | ADAR1 Capital Management Daniel Schneeberger | 130,000 | $78,039 | 0.01% | |
| 5. | LMR Partners Ben Levine, Andrew Manuel And Stefan Renold | 55,104 | $33,079 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.43 | 200,000 | $86,060.00 | 412,295 | 2025-05-16 | Filing | |
| $0.52 | 60,000 | $31,422.00 | 288,335 | 2025-05-20 | Filing | |
| $0.49 | 90,000 | $43,686.00 | 228,335 | 2025-05-19 | Filing | |
| $0.44 | 50,000 | $22,100.00 | 138,335 | 2025-05-16 | Filing | |
| $0.45 | 228,961 | $103,330.10 | 267,931 | 2025-05-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.32 | 4,068 | $74,525.76 | 88,774 | 2022-07-01 | Filing | |
| $18.45 | 8,848 | $163,245.60 | 92,842 | 2022-07-01 | Filing | |
| $18.48 | 839 | $15,504.72 | 101,690 | 2022-07-01 | Filing | |
| $19.01 | 10,698 | $203,368.98 | 88,774 | 2022-06-30 | Filing | |
| $19.37 | 5,314 | $102,932.18 | 99,472 | 2022-06-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 508,000 | $304,952 | 0% | |
| 2. | 396,514 | $238,027 | 0.04% | |
| 3. | 364,077 | $218,446 | 0% | |
| 4. | 302,354 | $181,541 | 0% | |
| 5. | 224,846 | $134,908 | 0% |
News See All
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript
Operator: Good afternoon. Welcome to the Relmada Therapeutics First Quarter 2025 Earnings Call.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Relmada Therapeutics, Incorporated Quarter 4 2024 Financial Results Call. At this time, all participants are in a listen-only mode.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2024 Earnings Call Transcript
Operator: Hello and welcome to the Relmada Therapeutics Third Quarter 2024 Earnings Conference Call.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2024 Earnings Call Transcript
Operator: Good afternoon. Welcome to the Relmada Therapeutics Inc.'s Second Quarter 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Relmada Therapeutics Inc. First Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript
Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.84, expectations were $-0.88.
11 Best Psychedelic Stocks to Buy in 2024
Unlike substances like marijuana or cocaine, psychedelics are potent and serve as a form of gateway to an 'alternate reality' for those who use them.
5 Most Promising Psychedelic Stocks According to Hedge Funds
In this piece, we will take a look at the five most promising psychedelic stocks according to hedge funds.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. And welcome to Relmada Therapeutics, Inc. Third Quarter 2023 Earnings Conference Call. At this time, all lines are in listen-only mode.
Billionaire Hedge Funds
